CA224-047: A randomized, double-blind, phase II/III study of relatlimab (anti–LAG-3) in combination with nivolumab (anti–PD-1) versus nivolumab alone in previously untreated metastatic or unresectable melanoma

Autor:	Christopher T. Harbison, Katy L. Simonsen, H.A. Tawbi, F.S. Hodi, Dirk Schadendorf, Victoria Atkinson, Georgina V. Long, Evan J. Lipson, Matthew Maurer
Rok vydání:	2018
Předmět:	0301 basic medicine Oncology medicine.medical_specialty business.industry Melanoma Anti pd 1 Hematology medicine.disease Double blind 03 medical and health sciences 030104 developmental biology 0302 clinical medicine 030220 oncology & carcinogenesis Internal medicine medicine Nivolumab business
Zdroj:	Annals of Oncology. 29:viii464-viii465
ISSN:	0923-7534
DOI:	10.1093/annonc/mdy289.058
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::2582f8ea7ebfed4f3fb06ef78bc0abee https://doi.org/10.1093/annonc/mdy289.058 Zobrazit plný text záznamu